27 USD
+0.21 (+0.78%)
27 USD
0 (0%)
We assign a fundamental rating of 6 out of 10 to AMPH. AMPH was compared to 191 industry peers in the Pharmaceuticals industry. While AMPH belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. AMPH scores decently on growth, while it is valued quite cheap. This could make an interesting combination. With these ratings, AMPH could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
In the past year AMPH was profitable.
AMPH had a positive operating cash flow in the past year.
AMPH had positive earnings in each of the past 5 years.
In the past 5 years AMPH always reported a positive cash flow from operatings.
1.2 Ratios
AMPH's Return On Assets of 6.70% is amongst the best of the industry. AMPH outperforms 87.96% of its industry peers.
Looking at the Return On Equity, with a value of 14.37%, AMPH belongs to the top of the industry, outperforming 88.48% of the companies in the same industry.
AMPH has a better Return On Invested Capital (8.51%) than 86.91% of its industry peers.
The Average Return On Invested Capital over the past 3 years for AMPH is in line with the industry average of 12.85%.
The 3 year average ROIC (12.92%) for AMPH is well above the current ROIC(8.51%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.7% | ||
| ROE | 14.37% | ||
| ROIC | 8.51% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
1.3 Margins
The Profit Margin of AMPH (15.43%) is better than 87.43% of its industry peers.
In the last couple of years the Profit Margin of AMPH has grown nicely.
AMPH has a better Operating Margin (20.73%) than 87.96% of its industry peers.
AMPH's Operating Margin has improved in the last couple of years.
With a decent Gross Margin value of 49.36%, AMPH is doing good in the industry, outperforming 63.87% of the companies in the same industry.
In the last couple of years the Gross Margin of AMPH has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.73% | ||
| PM (TTM) | 15.43% | ||
| GM | 49.36% |
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMPH is creating some value.
AMPH has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, AMPH has more shares outstanding
AMPH has a better debt/assets ratio than last year.
2.2 Solvency
AMPH has an Altman-Z score of 2.41. This is not the best score and indicates that AMPH is in the grey zone with still only limited risk for bankruptcy at the moment.
AMPH has a better Altman-Z score (2.41) than 62.30% of its industry peers.
AMPH has a debt to FCF ratio of 5.49. This is a neutral value as AMPH would need 5.49 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 5.49, AMPH belongs to the best of the industry, outperforming 81.68% of the companies in the same industry.
AMPH has a Debt/Equity ratio of 0.78. This is a neutral value indicating AMPH is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.78, AMPH is not doing good in the industry: 71.20% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | 5.49 | ||
| Altman-Z | 2.41 |
ROIC/WACC0.95
WACC8.92%
2.3 Liquidity
A Current Ratio of 3.12 indicates that AMPH has no problem at all paying its short term obligations.
The Current ratio of AMPH (3.12) is comparable to the rest of the industry.
A Quick Ratio of 2.21 indicates that AMPH has no problem at all paying its short term obligations.
AMPH has a Quick ratio of 2.21. This is comparable to the rest of the industry: AMPH outperforms 46.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.21 |
3. Growth
3.1 Past
The earnings per share for AMPH have decreased by -9.95% in the last year.
AMPH shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 61.62% yearly.
Looking at the last year, AMPH shows a decrease in Revenue. The Revenue has decreased by -0.03% in the last year.
AMPH shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.82% yearly.
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
3.2 Future
AMPH is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.14% yearly.
The Revenue is expected to grow by 4.14% on average over the next years.
EPS Next Y-8.73%
EPS Next 2Y-1.7%
EPS Next 3Y1.28%
EPS Next 5Y0.14%
Revenue Next Year-0.81%
Revenue Next 2Y2.1%
Revenue Next 3Y2.62%
Revenue Next 5Y4.14%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 7.85 indicates a rather cheap valuation of AMPH.
AMPH's Price/Earnings ratio is rather cheap when compared to the industry. AMPH is cheaper than 93.72% of the companies in the same industry.
AMPH is valuated cheaply when we compare the Price/Earnings ratio to 26.84, which is the current average of the S&P500 Index.
AMPH is valuated cheaply with a Price/Forward Earnings ratio of 7.24.
Based on the Price/Forward Earnings ratio, AMPH is valued cheaply inside the industry as 92.67% of the companies are valued more expensively.
AMPH's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.85 | ||
| Fwd PE | 7.24 |
4.2 Price Multiples
91.62% of the companies in the same industry are more expensive than AMPH, based on the Enterprise Value to EBITDA ratio.
AMPH's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AMPH is cheaper than 90.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.18 | ||
| EV/EBITDA | 7.42 |
4.3 Compensation for Growth
The excellent profitability rating of AMPH may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.13
EPS Next 2Y-1.7%
EPS Next 3Y1.28%
5. Dividend
5.1 Amount
No dividends for AMPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
27
+0.21 (+0.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners73.83%
Inst Owner Change0.4%
Ins Owners9.39%
Ins Owner Change-0.01%
Market Cap1.24B
Revenue(TTM)723.30M
Net Income(TTM)111.63M
Analysts80
Price Target32.35 (19.81%)
Short Float %11.45%
Short Ratio9.65
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.52%
Min EPS beat(2)10.58%
Max EPS beat(2)12.46%
EPS beat(4)3
Avg EPS beat(4)6.04%
Min EPS beat(4)-4.55%
Max EPS beat(4)12.46%
EPS beat(8)5
Avg EPS beat(8)4.79%
EPS beat(12)9
Avg EPS beat(12)18.2%
EPS beat(16)12
Avg EPS beat(16)16.54%
Revenue beat(2)1
Avg Revenue beat(2)0.23%
Min Revenue beat(2)-1.36%
Max Revenue beat(2)1.82%
Revenue beat(4)1
Avg Revenue beat(4)-1.21%
Min Revenue beat(4)-2.87%
Max Revenue beat(4)1.82%
Revenue beat(8)2
Avg Revenue beat(8)-0.96%
Revenue beat(12)6
Avg Revenue beat(12)0.35%
Revenue beat(16)9
Avg Revenue beat(16)0.62%
PT rev (1m)-2.12%
PT rev (3m)-4.47%
EPS NQ rev (1m)2.23%
EPS NQ rev (3m)1.91%
EPS NY rev (1m)3.62%
EPS NY rev (3m)2.59%
Revenue NQ rev (1m)0.88%
Revenue NQ rev (3m)-2.51%
Revenue NY rev (1m)0.61%
Revenue NY rev (3m)-0.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.85 | ||
| Fwd PE | 7.24 | ||
| P/S | 1.72 | ||
| P/FCF | 11.18 | ||
| P/OCF | 8.15 | ||
| P/B | 1.6 | ||
| P/tB | 6.07 | ||
| EV/EBITDA | 7.42 |
EPS(TTM)3.44
EY12.74%
EPS(NY)3.73
Fwd EY13.81%
FCF(TTM)2.42
FCFY8.95%
OCF(TTM)3.31
OCFY12.27%
SpS15.74
BVpS16.9
TBVpS4.45
PEG (NY)N/A
PEG (5Y)0.13
Graham Number36.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.7% | ||
| ROE | 14.37% | ||
| ROCE | 10.26% | ||
| ROIC | 8.51% | ||
| ROICexc | 10.49% | ||
| ROICexgc | 20.29% | ||
| OM | 20.73% | ||
| PM (TTM) | 15.43% | ||
| GM | 49.36% | ||
| FCFM | 15.35% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
ROICexc(3y)16.46%
ROICexc(5y)13%
ROICexgc(3y)29.66%
ROICexgc(5y)21.24%
ROCE(3y)15.59%
ROCE(5y)12.24%
ROICexgc growth 3Y24.9%
ROICexgc growth 5YN/A
ROICexc growth 3Y2.33%
ROICexc growth 5YN/A
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
F-Score5
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | 5.49 | ||
| Debt/EBITDA | 3 | ||
| Cap/Depr | 78.19% | ||
| Cap/Sales | 5.71% | ||
| Interest Coverage | 6.36 | ||
| Cash Conversion | 75.12% | ||
| Profit Quality | 99.44% | ||
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.21 | ||
| Altman-Z | 2.41 |
F-Score5
WACC8.92%
ROIC/WACC0.95
Cap/Depr(3y)91.01%
Cap/Depr(5y)109.44%
Cap/Sales(3y)5.45%
Cap/Sales(5y)6.46%
Profit Quality(3y)95%
Profit Quality(5y)414.14%
High Growth Momentum
Growth
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
EPS Next Y-8.73%
EPS Next 2Y-1.7%
EPS Next 3Y1.28%
EPS Next 5Y0.14%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
Revenue Next Year-0.81%
Revenue Next 2Y2.1%
Revenue Next 3Y2.62%
Revenue Next 5Y4.14%
EBIT growth 1Y-30.02%
EBIT growth 3Y43.24%
EBIT growth 5YN/A
EBIT Next Year1.38%
EBIT Next 3Y0.74%
EBIT Next 5Y5.95%
FCF growth 1Y-20.6%
FCF growth 3Y34.69%
FCF growth 5Y286.43%
OCF growth 1Y-12.89%
OCF growth 3Y29.62%
OCF growth 5Y38.57%
AMPHASTAR PHARMACEUTICALS IN / AMPH FAQ
What is the fundamental rating for AMPH stock?
ChartMill assigns a fundamental rating of 6 / 10 to AMPH.
Can you provide the valuation status for AMPHASTAR PHARMACEUTICALS IN?
ChartMill assigns a valuation rating of 8 / 10 to AMPHASTAR PHARMACEUTICALS IN (AMPH). This can be considered as Undervalued.
Can you provide the profitability details for AMPHASTAR PHARMACEUTICALS IN?
AMPHASTAR PHARMACEUTICALS IN (AMPH) has a profitability rating of 9 / 10.
How financially healthy is AMPHASTAR PHARMACEUTICALS IN?
The financial health rating of AMPHASTAR PHARMACEUTICALS IN (AMPH) is 6 / 10.
What is the expected EPS growth for AMPHASTAR PHARMACEUTICALS IN (AMPH) stock?
The Earnings per Share (EPS) of AMPHASTAR PHARMACEUTICALS IN (AMPH) is expected to decline by -8.73% in the next year.